A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors

NCT ID: NCT05940116

Last Updated: 2023-07-12

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 322 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-07-20
• Study Completion Date: 2027-07-30

Brief Summary

HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors.

Detailed Description

This is a multicenter, open-label, Phase I clinical study of HS-20117 to evaluate the safety, tolerability, PK, immunogenicity and efficacy in participants with advanced solid tumors. The study consists of phase Ia (dose escalation) and phase Ib (dose expansion). The dose-escalation study will be performed to evaluate the safety, tolerability, PK profile, immunogenicity, and efficacy of HS-20117 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The subsequent dose-expansion study will be performed to evaluate the efficacy of HS-20117 in participants with locally advanced or metastatic NSCLC who have progressed after prior platinum-based chemotherapy or are intolerant to platinum-based chemotherapy with EGFR exon 20 insertion mutations, and to explore the efficacy of HS-20117 in participants with other advanced solid tumors.

Conditions

Non-Small Cell Lung Cancer; Solid Tumor

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

HS-20117

Participants will receive IV infusion of HS-20117 once during cycle 1 and once every 2 weeks during subsequent cycles (The duration of each treatment cycle is 28 days)

Group Type: EXPERIMENTAL

HS-20117

Intervention Type: DRUG

Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined.

Phase Ib: patients will receive HS-20117 at MED or MAD

Interventions

HS-20117

Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined.

Phase Ib: patients will receive HS-20117 at MED or MAD

Intervention Type: DRUG

Other Intervention Names

PM1080

Eligibility Criteria

Inclusion Criteria

1. Males or females aged 18 - 75 years (inclusive).

2. For the phase Ia study: Participants with locally advanced or metastatic NSCLC (stage IIIB/IIIC/IV) with EGFR-activating mutations who have progressed after or are intolerant to or not available to standard of care (SoC).

3. For the phase Ib study:

Cohort A: Participants with locally advanced or metastatic NSCLC (stage IIIB/IIIC/IV) with EGFR exon 20ins mutations who have progressed after prior platinum-based chemotherapy or are intolerant to platinum-based chemotherapy.

Cohort B: Participants with other advanced solid tumors who have progressed after prior SoC or are intolerant to SoC.

4. Agree to provide fresh or archival tumor tissue.

5. At least one target lesion per the RECIST v1.1.

6. ECOG performance status of 0-1.

7. Minimum life expectancy > 12 weeks.

8. Males or Females should be using adequate contraceptive measures throughout the study.

9. Females must not be pregnant at screening or have evidence of non-childbearing potential.

10. Have signed Informed Consent Form.

Exclusion Criteria

1. Received or are receiving the following treatments:

1. For the phase Ib study Cohort A: Previous or current treatment with EGFR exon 20ins targeted therapy.

2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of HS-20117.

3. Cytotoxic chemotherapies, investigational drugs or other systematic anti-tumor therapies within 3 weeks prior to the first dose of HS-20117.

4. Antibodies within 4 weeks prior to the first dose of HS-20117.

5. Local radiotherapy within 2 weeks prior to the first dose of HS-20117, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of HS-20117.

6. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion.

7. Major surgery within 4 weeks prior to the first dose of HS-20117.

2. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy.

3. History of other primary malignancies.

4. Untreated, or active central nervous system metastases.

5. Inadequate bone marrow reserve or organ functions.

6. Severe, uncontrolled or active cardiovascular disorders.

7. Severe or uncontrolled systemic diseases.

8. Severe bleeding symptoms or bleeding tendencies within 1 month prior to the first dose of HS-20117.

9. Severe arteriovenous thrombosis occurred within 3 months prior to the first dose of HS-20117

10. Serious infection within 4 weeks prior to the first dose of HS-20117.

11. Active infectious diseases.

12. Interstitial lung disease (ILD).

13. Serious neurological or mental disorders.

14. History of hypersensitivity to any component of HS-20117 or similar drugs.

15. Participants with any condition that compromises the safety of the participant or interferes with the assessment of the study, as judged by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hansoh BioMedical R&D Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dingzhi Huang

Role: PRINCIPAL_INVESTIGATOR

Tianjin Medical University Cancer Institute and Hospital

Locations

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Countries

China

Central Contacts

Peng Zhou

Role: CONTACT

zhoup7@hspharm.com

+86 18013002767

Facility Contacts

Lin Jiang

Role: primary

jianglinchn@163.com

+86 022-23340123 ext. 6417

Other Identifiers

HS-20117-101

Identifier Type: -

Identifier Source: org_study_id